Vaxcyte (NASDAQ:PCVX) CAO Sells $105,138.44 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CAO Elvia Cowan sold 1,892 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $55.57, for a total value of $105,138.44. Following the sale, the chief accounting officer owned 28,975 shares in the company, valued at approximately $1,610,140.75. This represents a 6.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Elvia Cowan also recently made the following trade(s):

• On Wednesday, March 11th, Elvia Cowan sold 2,500 shares of Vaxcyte stock. The stock was sold at an average price of $58.59, for a total value of $146,475.00.
• On Tuesday, December 23rd, Elvia Cowan sold 11,623 shares of Vaxcyte stock. The shares were sold at an average price of $47.92, for a total value of $556,974.16.

Vaxcyte Trading Down 2.2%

Shares of Vaxcyte stock traded down $1.20 during trading on Wednesday, hitting $54.28. 1,045,542 shares of the company’s stock traded hands, compared to its average volume of 1,266,037. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $76.61. The business has a 50-day simple moving average of $54.49 and a 200-day simple moving average of $46.36.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, February 24th. The company reported ($1.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.46) by ($0.34). During the same period last year, the firm earned ($1.12) earnings per share. On average, sell-side analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PCVX. BTIG Research increased their price objective on shares of Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Guggenheim reaffirmed a “buy” rating and issued a $116.00 target price on shares of Vaxcyte in a research report on Monday, February 2nd. Leerink Partners set a $77.00 target price on shares of Vaxcyte and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a report on Tuesday, March 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $94.50.

Institutional Investors Weigh In On Vaxcyte

A number of hedge funds have recently modified their holdings of PCVX. Smartleaf Asset Management LLC grew its stake in shares of Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in shares of Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after purchasing an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after buying an additional 184 shares in the last quarter. Allworth Financial LP boosted its stake in Vaxcyte by 148.9% during the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after buying an additional 731 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in Vaxcyte during the third quarter valued at approximately $45,000. Institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.